Chronic Inflammatory Demyelinating Polyneuropathy
Q&A: ‘Exciting time’ for research into, development of treatments for CIDP
Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.
FDA approves Vyvgart for chronic inflammatory demyelinating polyneuropathy
The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy, according to the manufacturer.
European Commission approves Hyqvia for chronic inflammatory demyelinating polyneuropathy
The European Commission has approved Hyqvia as maintenance therapy for individuals of all ages with chronic inflammatory demyelinating polyneuropathy.
FDA approves IV immunoglobulin therapy for CIDP in adults
The FDA has approved Gammagard Liquid as an IV immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy.
FDA approves Hyqvia for chronic inflammatory demyelinating polyneuropathy
The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery technology, to treat chronic inflammatory demyelinating polyneuropathy in adults.